Washington, DC (September 13, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Scott Olsen will join the association as senior vice president for federal advocacy. A seasoned Democratic strategist, Olsen returns to PhRMA on October 3, 2016 to lead PhRMA’s federal government relations team.
Olsen is a recognized leader in federal government relations with over 20 years of experience working with Democrats and Republicans on Medicare and Medicaid policy. He began his career working in the office of then-Senator Max Baucus (D-MT). As the Senator’s top health policy aide, he supported the Senator’s health care work on the Senate Finance Committee. He previously spent several years at PhRMA as both the lead Democratic lobbyist and Senate team leader. During that time he worked closely on the passage of the Medicare Modernization Act in 2003.
“As PhRMA continues to tell the story of the life-changing work of America’s biopharmaceutical companies while advocating for patient access to new treatments, Scott’s experience finding common ground with Democrats and Republicans is a vital addition to the association,” said Stephen J. Ubl, president and CEO of PhRMA.
Olsen most recently spent nearly a decade with Amgen, Inc. including as executive director of federal government affairs in Washington, D.C. Fluent in Japanese, Olsen was subsequently promoted to manage Amgen’s investment opportunities in Japan, China, Russia and the European Union.
“This is an exciting time in America’s biopharmaceutical industry as companies continue the tireless work of researching and developing new treatments and cures for patients,” Olsen said. “I am especially looking forward to helping PhRMA advance bipartisan solutions to our nation’s health care challenges.”
Following his years of service to Senator Baucus, Olsen was a Mike Mansfield Fellow with the Japanese Department of Health and Welfare. He holds a bachelor’s degree and graduated magna cum laude from Boston University and completed foreign affairs training with the U.S. Department of State.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.